Mobile

A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures

Update Il y a 4 ans
Reference: EUCTR2007-003307-13

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the minimum effective dose (MED) of intranasal clonazepam, defined as the lowest dose that can effectively reduce epileptiform activity in adult epilepsy subjects over the 24 hours following the onset of an epileptic seizure.

Inclusion criteria

  • Recurrent Acute Repetitive Seizures (ARS)

Links